Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
| ▸ | DRD4 | P21917 | 1/20 | 0.30 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1152677 | 0.77 | OPRM1 (0.49) | CHRM1OPRM1OPRD1DRD2DRD4 | |
| SCHEMBL10640876 | 0.76 | OPRM1 (0.49) | OPRM1OPRD1 | |
| SCHEMBL10637592 | 0.74 | OPRM1 (0.46) | OPRM1DRD2 | |
| SCHEMBL10637222 | 0.74 | OPRM1 (0.50) | OPRM1DRD2 | |
| SCHEMBL14534173 | 0.72 | OPRM1 (0.37) | CHRM1OPRM1HRH4DRD2HTR6 | |
| SCHEMBL10641018 | 0.72 | POLB (0.42) | OPRM1DRD4CHRNA7 | |
| SCHEMBL5754499 | 0.72 | KMT2A (0.43) | CHRM1OPRM1OPRD1 | |
| SCHEMBL11068281 | 0.72 | ALDH1A1 (0.43) | OPRD1DRD2DRD4 | |
| SCHEMBL11074351 | 0.72 | SLC6A4 (0.43) | CHRM1OPRM1OPRD1 | |
| SCHEMBL11074405 | 0.72 | OPRL1 (0.39) | OPRM1OPRD1HRH4DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1441718-B1 | USE OF CARBINOLS FOR THE TREATMENT OF NEUROPATHIC DYSFUNCTION | ENDO PHARMACEUTICALS INC (US) | 2006-07-12 | — | — | EP | claimed |
| EP-1441718-A4 | CARBINOLS FOR THE TREATMENT OF NEUROPATHIC DYSFUNCTION | ENDO PHARMACEUTICALS INC (US) | 2005-08-17 | — | — | EP | claimed |
| US-6825217-B2 | HETEROCYCLIC AMINES SUCH AS 4-(3'-THIENYL)-ALPHA, ALPHA, 1-TRIMETHYL-4-PIPERIDINEMETHANOL AND/OR PRODRUGS, USED AS ANALGESICS FOR PROPHYLAXIS OF NEUROPATHIC PAIN | ENDO PHARMACEUTICALS, INC. | 2004-11-30 | — | — | US | claimed |
| EP-1441718-A2 | CARBINOLS FOR THE TREATMENT OF NEUROPATHIC DYSFUNCTION | Endo Pharmaceuticals Inc. (US) | 2004-08-04 | — | — | EP | claimed |
| US-20030162811-A1 | Carbinols for the treatment of neuropathic dysfunction | ENDO PHARMACEUTICALS INC. | 2003-08-28 | — | — | US | claimed |
| WO-2003032910-A2 | CARBINOLS FOR THE TREATMENT OF NEUROPATHIC DYSFUNCTION | ENDO PHARMACEUTICALS INC. (US) | 2003-04-24 | — | — | WO | claimed |
| US-5086063-A | Analgesics, antidepressants, anorexigenic agents | DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-02-04 | — | — | US | claimed |
| US-5019650-A | 4-aryl-4-piperidine (or pyrrolidine or hexahydroazepine) carbinols and heterocyclic analogs thereof | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-05-28 | — | — | US | claimed |
| EP-1441718-B1 | USE OF CARBINOLS FOR THE TREATMENT OF NEUROPATHIC DYSFUNCTION | ENDO PHARMACEUTICALS INC (US) | 2006-07-12 | — | — | EP | disclosed |
| EP-1441718-A4 | CARBINOLS FOR THE TREATMENT OF NEUROPATHIC DYSFUNCTION | ENDO PHARMACEUTICALS INC (US) | 2005-08-17 | — | — | EP | disclosed |
| US-20050026956-A1 | 3-Aryl-3-pyrrolidinemethanol, 4-aryl-4-piperidinemethanol, or 4-aryl-4-azepinemethanol derivatives; 4-(3-thienyl)- alpha , alpha ,1,1-trimethyl-4-piperidinemethanol; tumors, diabetes, arthritis; autoimmune, genetic, demyelination, and rheumatic disorders; antiinflammatory agents | ENDO PHARMACEUTICALS, INC., A DELAWARE CORPORATION (US) | 2005-02-03 | — | — | US | disclosed |
| US-6825217-B2 | HETEROCYCLIC AMINES SUCH AS 4-(3'-THIENYL)-ALPHA, ALPHA, 1-TRIMETHYL-4-PIPERIDINEMETHANOL AND/OR PRODRUGS, USED AS ANALGESICS FOR PROPHYLAXIS OF NEUROPATHIC PAIN | ENDO PHARMACEUTICALS, INC. | 2004-11-30 | — | — | US | disclosed |
| EP-1441718-A2 | CARBINOLS FOR THE TREATMENT OF NEUROPATHIC DYSFUNCTION | Endo Pharmaceuticals Inc. (US) | 2004-08-04 | — | — | EP | disclosed |
| US-20030162811-A1 | Carbinols for the treatment of neuropathic dysfunction | ENDO PHARMACEUTICALS INC. | 2003-08-28 | — | — | US | disclosed |
| WO-2003032910-A2 | CARBINOLS FOR THE TREATMENT OF NEUROPATHIC DYSFUNCTION | ENDO PHARMACEUTICALS INC. (US) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162811-A1 | Carbinols for the treatment of neuropathic dysfunction | CNR2, CNR1, OPRL1 | CHRM1 567/4885OPRM1 11/4885OPRD1 7/4885 |
| US-20050026956-A1 | 3-Aryl-3-pyrrolidinemethanol, 4-aryl-4-piperidinemethanol, or 4-aryl-4-azepinemethanol derivatives; 4-(3-thienyl)- alpha , alpha ,1,1-trimethyl-4-piperidinemethanol; tumors, diabetes, arthritis; autoimmune, genetic, demyelination, and rheumatic disorders; antiinflammatory agents | PMP22, NAT1, MAG | CHRM1 1464/4885OPRM1 227/4885OPRD1 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.